Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:ICAD NASDAQ:MBOT NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.97+19.8%$0.90$0.69▼$1.80$26.29M-2.58163,170 shs587,383 shsICADicad$3.87$3.81$1.19▼$4.02$106.31M1.37426,282 shsN/AMBOTMicrobot Medical$2.88+8.7%$2.58$0.82▼$3.38$96.40M1.152.12 million shs1.71 million shsSLNOSoleno Therapeutics$81.63-3.0%$82.20$41.50▼$90.32$4.24B-2.561.47 million shs843,686 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys+19.84%+15.57%+3.72%-14.50%-3.13%ICADicad0.00%0.00%+2.79%+7.50%+204.72%MBOTMicrobot Medical+8.68%+7.46%+10.77%+14.74%+225.57%SLNOSoleno Therapeutics-2.96%-2.79%-5.78%+9.34%+80.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFEMYFemasys2.8131 of 5 stars3.55.00.00.00.02.50.6ICADicadN/AN/AN/AN/AN/AN/AN/AN/AMBOTMicrobot Medical1.6686 of 5 stars3.51.00.00.02.40.00.6SLNOSoleno Therapeutics4.2307 of 5 stars3.51.00.04.63.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$8.67794.67% UpsideICADicad 2.00HoldN/AN/AMBOTMicrobot Medical 3.00Buy$9.00212.50% UpsideSLNOSoleno Therapeutics 3.09Buy$108.7033.16% UpsideCurrent Analyst Ratings BreakdownLatest FEMY, SLNO, MBOT, and ICAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$105.00 ➝ $121.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.00(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M19.33N/AN/A$0.10 per share9.69ICADicad$19.61M5.42N/AN/A$1.08 per share3.58MBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/ASLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)ICADicad-$5.62M-$0.19N/A∞N/A-26.63%-15.03%-11.77%8/12/2025 (Estimated)MBOTMicrobot Medical-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)Latest FEMY, SLNO, MBOT, and ICAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/AFEMYFemasys-$0.18N/AN/AN/AN/AN/A8/13/2025N/AMBOTMicrobot Medical-$0.08N/AN/AN/AN/AN/A8/12/2025Q2 2025ICADicad-$0.0550N/AN/AN/A$4.81 millionN/A8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.85N/AN/AN/A$3.91 millionN/A5/21/2025Q1 2025MBOTMicrobot Medical-$0.15-$0.08+$0.07-$0.08N/AN/A5/13/2025Q1 2025ICADicad-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AICADicadN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.020.930.54ICADicadN/A3.663.57MBOTMicrobot MedicalN/A16.1916.19SLNOSoleno Therapeutics0.2119.6419.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%ICADicad24.61%MBOTMicrobot Medical16.30%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%ICADicad10.29%MBOTMicrobot Medical4.74%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.53 million28.77 millionNot OptionableICADicad14027.47 million24.64 millionOptionableMBOTMicrobot Medical2036.38 million34.65 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableFEMY, SLNO, MBOT, and ICAD HeadlinesRecent News About These CompaniesSoleno Therapeutics's Earnings: A Preview2 hours ago | benzinga.comWestfield Capital Management Co. LP Acquires 329,785 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)August 4 at 4:19 AM | marketbeat.comVictory Capital Management Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)August 3 at 3:18 AM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Recommendation of "Buy" from AnalystsAugust 3 at 2:37 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 3 at 2:35 AM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Bought by TD Asset Management IncAugust 2, 2025 | marketbeat.comXTX Topco Ltd Boosts Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)August 1, 2025 | marketbeat.comSoleno Therapeutics (SLNO) to Release Quarterly Earnings on WednesdayJuly 30, 2025 | marketbeat.comRoyce & Associates LP Invests $286,000 in Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 30, 2025 | marketbeat.com36,495 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Universal Beteiligungs und Servicegesellschaft mbHJuly 30, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Purchases 15,101 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 29, 2025 | marketbeat.comRWC Asset Management LLP Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 28, 2025 | marketbeat.comBryce Point Capital LLC Decreases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 28, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI) and Soleno Therapeutics (SLNO)July 27, 2025 | theglobeandmail.comLegato Capital Management LLC Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 26, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Raised to "Hold" at Wall Street ZenJuly 26, 2025 | marketbeat.comSoleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?July 25, 2025 | zacks.comHere's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price StrengthJuly 23, 2025 | msn.comCan Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?July 23, 2025 | zacks.com40,425 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Purchased by Y Intercept Hong Kong LtdJuly 23, 2025 | marketbeat.comReadystate Asset Management LP Buys 49,422 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFEMY, SLNO, MBOT, and ICAD Company DescriptionsFemasys NASDAQ:FEMY$0.97 +0.16 (+19.84%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$0.92 -0.05 (-5.44%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.icad NASDAQ:ICAD$3.87 0.00 (0.00%) As of 07/17/2025iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.Microbot Medical NASDAQ:MBOT$2.88 +0.23 (+8.68%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$2.88 0.00 (0.00%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Soleno Therapeutics NASDAQ:SLNO$81.63 -2.49 (-2.96%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$90.00 +8.37 (+10.25%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Soars After Blowout Earnings Report Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? Applied Digital: Why a Surge in Bullish Bets Signals a New Era META Gets Huge Upgrades: How High Analysts Think Shares Could Go Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
